FDA Proposes Streamlining Intercenter Agreements On Combo Products
This article was originally published in The Gray Sheet
Executive Summary
FDA is proposing to rescind an intercenter agreement between the Center for Biologics Evaluation & Research (CBER) and the Center for Drug Evaluation & Research (CDER) in order to modernize its oversight of combination products